Vimarsana
Biggest News Aggregation in the World

Page 8 - Cell Line Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cell Line Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cell Line Development Today - Breaking & Trending Today

4 upcoming webinars to empower your research - Vimarsana News

4 upcoming webinars to empower your research

Discover the latest tools and techniques to expand your research capacity with these expert-led presentations

Global Cell Line Development Market Outlook 2022-2031: Increasing Demand for Monoclonal Antibodies Fuels Growth - Vimarsana News

Global Cell Line Development Market Outlook 2022-2031: Increasing Demand for Monoclonal Antibodies Fuels Growth

/PRNewswire/ -- The "Global Cell Line Development Market Outlook 2031" report has been added to ResearchAndMarkets.com's offering. The global cell line...

Upcoming biopharmaceutical webinars to boost your research - Vimarsana News

Upcoming biopharmaceutical webinars to boost your research

Discover the latest biopharmaceutical tools and techniques with these expert-led presentations

BrickBio Achieves Stable Cell Line in Record Timeframe: 5x Faster with 7x Enhanced Production for Single or Multiple Distinct Bioconjugation Handles - Vimarsana News

BrickBio Achieves Stable Cell Line in Record Timeframe: 5x Faster with 7x Enhanced Production for Single or Multiple Distinct Bioconjugation Handles

/PRNewswire/ -- BrickBio has overcome previous limitations in unnatural amino acid (UAA) driven site-specific conjugation by achieving stable, mammalian cell...

Another Clinical Asset Using ProBioGen's GlymaxX® Technology Begins Phase III - Vimarsana News

Another Clinical Asset Using ProBioGen's GlymaxX® Technology Begins Phase III

BERLIN, Germany, January 26, 2023 / B3C newswire / -- ProBioGen today announced that a Novartis clinical candidate using its antibody-dependent cellular cytotoxicity (ADCC) technology, GlymaxX, has reached Phase III.ProBioGen's mission is to contribute towards the development of medicines against complex diseases. T...